Nanotherapeutic approaches for brain cancer management

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 5, 2014, Pages e905-e919

  Saenz del Burgo, Laura ^a,b   Hernández, Rosa María ^a,b   Orive, Gorka ^a,b   Pedraz, Jose Luis ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Anticancer drugs; Biomaterials; Drug delivery; Magnetic therapy; Targeted delivery

Indexed keywords

BIOMATERIALS; CLINICAL RESEARCH; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; DRUG DELIVERY; GENE THERAPY; NANOPARTICLES; PHYSICAL THERAPY; TUMORS;

ANTI-ANGIOGENIC THERAPY; ANTICANCER DRUG; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; MAGNETIC THERAPY; RESEARCH RESULTS; SYSTEMIC ADMINISTRATION; TARGETED DELIVERY;

TARGETED DRUG DELIVERY;

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARMUSTINE; DENDRIMER; DOXORUBICIN; LIPID; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCARRIER; PACLITAXEL; POLYMER; VINCRISTINE; VINCRISTINE SULFATE; NANOPARTICLE;

ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HUMAN; HYPERTHERMIC THERAPY; INFUSION SYSTEM; LOCAL THERAPY; MAGNETOTHERAPY; MICELLE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; THERAPY EFFECT; BRAIN NEOPLASMS; CHEMISTRY; PROCEDURES;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES;

EID: 84903543845     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.10.001     Document Type: Review

References (140)

1. Mehta M., Vogelbaum M., Chang S. Neoplasms of the central nervous system. Cancer: principles and practice of oncology 2011, 1700-1749. Lippincott Williams & Wilkins. 9th ed.
2. Dolecek T.A., Propp J.M., Stroup N.E., Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012, 14(Suppl. 5):v1-v49.
3. Ferlay J., Shin H., Bray F., Forman D., Mathers C., Parkin M. GLOBOCAN 2008 v3.0, Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. International Agency for Research on Cancer. 2010. Lyon, France. 10-1-2013 2010, Ref Type: Online Source; available at:. http://globocan.iarc.fr/.
4. Westphal M., Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 2011, 12(9):495-508.
5. Classification of tumors of the central nervous system 2007 2013, World Health Organization (WHO), Ref Type: Online Source, available at:. http://www.brainlife.org/classification/who2007.htm.
6. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109.
7. Walker M.D., Alexander E., Hunt W.E., MacCarty C.S., Mahaley M.S., Mealey J., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49(3):333-343.
8. Clarke J., Butowski N., Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010, 67(3):279-283.
9. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
10. Allard E., Passirani C., Benoit J.P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009, 30(12):2302-2318.
11. Ewend M.G., Brem S., Gilbert M., Goodkin R., Penar P.L., Varia M., et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007, 13(12):3637-3641.
12. Barr J.G., Grundy P.L. The effects of the NICE Technology Appraisal 121 (Gliadel and temozolomide) on survival in high-grade glioma. Br J Neurosurg 2012, 26(6):818-822.
13. Bernacki J., Dobrowolska A., Nierwinska K., Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008, 60(5):600-622.
14. Spector R. Drug transport in the mammalian central nervous system: multiple complex systems. A critical analysis and commentary. Pharmacology 2000, 60(2):58-73.
15. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57(2):173-185.
16. Sura P., Sura R., EnayetAllah A.E., Grant D.F. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 2008, 56(6):551-559.
17. Agarwal S., Manchanda P., Vogelbaum M.A., Ohlfest J.R., Elmquist W.F. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013, 41(1):33-39.
18. Pardridge W.M. Blood-brain barrier delivery. Drug Discov Today 2007, 12(1-2):54-61.
19. Nichols J.W., Bae Y.H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 2012, 7(6):606-618.
20. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
21. Dhanikula R.S., Argaw A., Bouchard J.F., Hildgen P. Methotrexate loaded poly-ether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008, 5(1):105-116.
22. Li Y., He H., Jia X., Lu W.L., Lou J., Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 2012, 33(15):3899-3908.
23. Orive G., Anitua E., Pedraz J.L., Emerich D.F. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009, 10(9):682-692.
24. Alam M.I., Beg S., Samad A., Baboota S., Kohli K., Ali J., et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010, 40(5):385-403.
25. Egusquiaguirre S.P., Igartua M., Hernández R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 2012, 14(2):83-93.
26. Thanh N., Green L. Functionalisation of nanoparticles for biomedical applications. Nano Today 2010, 5:213-230.
27. Meyers J.D., Doane T., Burda C., Basilion J.P. Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) 2013, 8(1):123-143.
28. Basile L., Passirani C., Huynh N.T., Bejaud J., Benoit J.P., Puglisi G., et al. Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative. Int J Pharm 2012, 426(1-2):231-238.
29. Huynh N.T., Morille M., Bejaud J., Legras P., Vessieres A., Jaouen G., et al. Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharm Res 2011, 28(12):3189-3198.
30. Allard E., Passirani C., Garcion E., Pigeon P., Vessieres A., Jaouen G., et al. Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. J Control Release 2008, 130(2):146-153.
31. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12(1):62-76.
32. Chang H.I., Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012, 7:49-60.
33. Dickinson P.J., Lecouteur R.A., Higgins R.J., Bringas J.R., Roberts B., Larson R.F., et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 2008, 108(5):989-998.
34. Miyata S., Kawabata S., Hiramatsu R., Doi A., Ikeda N., Yamashita T., et al. Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. Neurosurgery 2011, 68(5):1380-1387.
35. Deng C., Jiang Y.J., Cheng R., Meng F.H., Zhong Z.Y. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 2012, 7(5):467-480.
36. Owen S.C., Chan D.P.Y., Shoichet M.S. Polymeric micelle stability. Nano Today 2012, 7(1):53-65.
37. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6(12):815-823.
38. Kim S., Shi Y., Kim J.Y., Park K., Cheng J.X. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv 2010, 7(1):49-62.
39. Kaminskas L.M., McLeod V.M., Porter C.J., Boyd B.J. Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. Mol Pharm 2012, 9(3):355-373.
40. Shen M., Shi X. Dendrimer-based organic/inorganic hybrid nanoparticles in biomedical applications. Nanoscale 2010, 2(9):1596-1610.
41. Holden C.A., Yuan Q., Yeudall W.A., Lebman D.A., Yang H. Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery. Int J Nanomedicine 2010, 5:25-36.
42. Huynh G.H., Deen D.F., Szoka F.C. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 2006, 110(2):236-259.
43. Hassenbusch S.J., Nardone E.M., Levin V.A., Leeds N., Pietronigro D. Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia 2003, 5(1):9-16.
44. Roger M., Clavreul A., Venier-Julienne M.C., Passirani C., Montero-Menei C., Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011, 32(8):2106-2116.
45. Roger M., Clavreul A., Huynh N.T., Passirani C., Schiller P., Vessieres A., et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 2012, 423(1):63-68.
46. Lee J.H., Jang J.T., Choi J.S., Moon S.H., Noh S.H., Kim J.W., et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol 2011, 6(7):418-422.
47. Ammaya A.K. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet 1963, 2(7315):983-984.
48. Walter K.A., Tamargo R.J., Olivi A., Burger P.C., Brem H. Intratumoral chemotherapy. Neurosurgery 1995, 37(6):1128-1145.
49. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994, 91(6):2076-2080.
50. Astary G.W., Kantorovich S., Carney P.R., Mareci T.H., Sarntinoranont M. Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo. J Neurosci Methods 2010, 187(1):129-137.
51. Cunningham J., Pivirotto P., Bringas J., Suzuki B., Vijay S., Sanftner L., et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 2008, 16(7):1267-1275.
52. Lidar Z., Mardor Y., Jonas T., Pfeffer R., Faibel M., Nass D., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004, 100(3):472-479.
53. Laske D.W., Youle R.J., Oldfield E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997, 3(12):1362-1368.
54. Debinski W., Obiri N.I., Pastan I., Puri R.K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995, 270(28):16775-16780.
55. MacKay J.A., Deen D.F., Szoka F.C. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005, 1035(2):139-153.
56. Chen M.Y., Hoffer A., Morrison P.F., Hamilton J.F., Hughes J., Schlageter K.S., et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 2005, 103(2):311-319.
57. Perlstein B., Ram Z., Daniels D., Ocherashvilli A., Roth Y., Margel S., et al. Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring. Neuro Oncol 2008, 10(2):153-161.
58. Mardor Y., Rahav O., Zauberman Y., Lidar Z., Ocherashvilli A., Daniels D., et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res 2005, 65(15):6858-6863.
59. Saito R., Krauze M.T., Noble C.O., Drummond D.C., Kirpotin D.B., Berger M.S., et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol 2006, 8(3):205-214.
60. Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., Kirpotin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006, 66(6):3271-3277.
61. Park J.W., Hong K., Kirpotin D.B., Meyer O., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997, 118(2):153-160.
62. Laine A.L., Huynh N.T., Clavreul A., Balzeau J., Bejaud J., Vessieres A., et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur J Pharm Biopharm 2012, 81(3):690-693.
63. Yamashita Y., Krauze M.T., Kawaguchi T., Noble C.O., Drummond D.C., Park J.W., et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol 2007, 9(1):20-28.
64. Allard E., Jarnet D., Vessieres A., Vinchon-Petit S., Jaouen G., Benoit J.P., et al. Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft. Pharm Res 2010, 27(1):56-64.
65. Wu G., Yang W., Barth R.F., Kawabata S., Swindall M., Bandyopadhyaya A.K., et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 2007, 13(4):1260-1268.
66. Cirpanli Y., Allard E., Passirani C., Bilensoy E., Lemaire L., Calis S., et al. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 2011, 403(1-2):201-206.
67. Brem H., Mahaley M.S., Vick N.A., Black K.L., Schold S.C., Burger P.C., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991, 74(3):441-446.
68. Attenello F.J., Mukherjee D., Datoo G., McGirt M.J., Bohan E., Weingart J.D., et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008, 15(10):2887-2893.
69. Duntze J., Litre C.F., Eap C., Theret E., Debreuve A., Jovenin N., et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol 2012, 10.1245/s10434-012-2764-x.
70. La Rocca R.V., Mehdorn H.M. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 2009, 25(1):149-160.
71. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
72. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5(2):79-88.
73. Bock H.C., Puchner M.J., Lohmann F., Schutze M., Koll S., Ketter R., et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010, 33(4):441-449.
74. McGirt M.J., Than K.D., Weingart J.D., Chaichana K.L., Attenello F.J., Olivi A., et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009, 110(3):583-588.
75. Noel G., Schott R., Froelich S., Gaub M.P., Boyer P., Fischer-Lokou D., et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2012, 82(2):749-755.
76. De B.P., Anile C., Pompucci A., Fiorentino A., Balducci M., Chiesa S., et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 2012, 154(8):1371-1378.
77. Ko A.L., Fink K.R., Stelzer K.M., Silbergeld D.L. Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma. Surg Neurol Int 2012, 3:137.
78. McPherson C.M., Gerena-Lewis M., Breneman J.C., Warnick R.E. Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy. J Neurooncol 2012, 108(3):521-525.
79. Recinos V.R., Tyler B.M., Bekelis K., Sunshine S.B., Vellimana A., Li K.W., et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 2010, 66(3):530-537.
80. Scott A.W., Tyler B.M., Masi B.C., Upadhyay U.M., Patta Y.R., Grossman R., et al. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials 2011, 32(10):2532-2539.
81. Elstad N.L., Fowers K.D. OncoGel (ReGel/paclitaxel)-clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009, 61(10):785-794.
82. Jeong B., Bae Y.H., Kim S.W. In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof. J Biomed Mater Res 2000, 50(2):171-177.
83. Tyler B., Fowers K.D., Li K.W., Recinos V.R., Caplan J.M., Hdeib A., et al. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg 2010, 113(2):210-217.
84. Brem S., Tyler B., Li K., Pradilla G., Legnani F., Caplan J., et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 2007, 60(5):643-650.
85. Vellimana A.K., Recinos V.R., Hwang L., Fowers K.D., Li K.W., Zhang Y., et al. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J Neurooncol 2013, 111(3):229-236.
86. Cahan M.A., Walter K.A., Colvin O.M., Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994, 33(5):441-444.
87. Tishler R.B., Geard C.R., Hall E.J., Schiff P.B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992, 52(12):3495-3497.
88. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., TN de, Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
89. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50(19):6119-6129.
90. Santini J.T., Cima M.J., Langer R. A controlled-release microchip. Nature 1999, 397(6717):335-338.
91. Santini J.T., Richards A.C., Scheidt R.A., Cima M.J., Langer R.S. Microchip technology in drug delivery. Ann Med 2000, 32(6):377-379.
92. Kim G.Y., Tyler B.M., Tupper M.M., Karp J.M., Langer R.S., Brem H., et al. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release 2007, 123(2):172-178.
93. Masi B.C., Tyler B.M., Bow H., Wicks R.T., Xue Y., Brem H., et al. Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. Biomaterials 2012, 33(23):5768-5775.
94. Li Y., Ho Duc H.L., Tyler B., Williams T., Tupper M., Langer R., et al. In vivo delivery of BCNU from a MEMS device to a tumor model. J Control Release 2005, 106(1-2):138-145.
95. Grossman S.A., Reinhard C., Colvin O.M., Chasin M., Brundrett R., Tamargo R.J., et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992, 76(4):640-647.
96. Sampson J.H., Archer G., Pedain C., Wembacher-Schroder E., Westphal M., Kunwar S., et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 2010, 113(2):301-309.
97. Engelhard H.H. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000, 53(5):458-464.
98. Weber E.L., Goebel E.A. Cerebral edema associated with Gliadel wafers: two case studies. Neuro Oncol 2005, 7(1):84-89.
99. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012, 164(2):138-144.
100. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
101. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161(2):175-187.
102. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99(3):392-397.
103. Jaracz S., Chen J., Kuznetsova L.V., Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005, 13(17):5043-5054.
104. Talelli M., Oliveira S., Rijcken C.J., Pieters E.H., Etrych T., Ulbrich K., et al. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 2013, 34(4):1255-1260.
105. Muyldermans S., Baral T.N., Retamozzo V.C., De B.P., De G.E., Kinne J., et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 2009, 128(1-3):178-183.
106. Mickler F.M., Mockl L., Ruthardt N., Ogris M., Wagner E., Brauchle C. Tuning nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand. Nano Lett 2012, 12(7):3417-3423.
107. Chekhonin V.P., Baklaushev V.P., Yusubalieva G.M., Belorusova A.E., Gulyaev M.V., Tsitrin E.B., et al. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43. Nanomedicine 2012, 8(1):63-70.
108. Bello L., Francolini M., Marthyn P., Zhang J., Carroll R.S., Nikas D.C., et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001, 49(2):380-389.
109. Chen X., Park R., Shahinian A.H., Tohme M., Khankaldyyan V., Bozorgzadeh M.H., et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004, 31(2):179-189.
110. Zhan C., Qian J., Feng L., Zhong G., Zhu J., Lu W. Cyclic RGD-poly(ethylene glycol)-polyethyleneimine is more suitable for glioblastoma targeting gene transfer in vivo. J Drug Target 2011, 19(7):573-581.
111. Zhan C., Meng Q., Li Q., Feng L., Zhu J., Lu W. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery. Chem Asian J 2012, 7(1):91-96.
112. Zhan C., Gu B., Xie C., Li J., Liu Y., Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 2010, 143(1):136-142.
113. Zhan C., Wei X., Qian J., Feng L., Zhu J., Lu W. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Control Release 2012, 160(3):630-636.
114. Zhan C., Li B., Hu L., Wei X., Feng L., Fu W., et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed Engl 2011, 50(24):5482-5485.
115. Chang J., Paillard A., Passirani C., Morille M., Benoit J.P., Betbeder D., et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res 2012, 29(6):1495-1505.
116. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987, 18(2):299-304.
117. Zhang P., Hu L., Yin Q., Zhang Z., Feng L., Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release 2012, 159(3):429-434.
118. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141(2):183-192.
119. Liu S., Guo Y., Huang R., Li J., Huang S., Kuang Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33(19):4907-4916.
120. Wu X.X., Kakehi Y., Mizutani Y., Kamoto T., Kinoshita H., Isogawa Y., et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002, 20(5):949-954.
121. Xin H., Jiang X., Gu J., Sha X., Chen L., Law K., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32(18):4293-4305.
122. Rozhkova E.A., Ulasov I., Lai B., Dimitrijevic N.M., Lesniak M.S., Rajh T. A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett 2009, 9(9):3337-3342.
123. Feng B., Tomizawa K., Michiue H., Miyatake S., Han X.J., Fujimura A., et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009, 30(9):1746-1755.
124. Wagner S., Rothweiler F., Anhorn M.G., Sauer D., Riemann I., Weiss E.C., et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010, 31(8):2388-2398.
125. Zhou J., Liu J., Cheng C.J., Patel T.R., Weller C.E., Piepmeier J.M., et al. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat Mater 2012, 11(1):82-90.
126. Agemy L., Friedmann-Morvinski D., Kotamraju V.R., Roth L., Sugahara K.N., Girard O.M., et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A 2011, 108(42):17450-17455.
127. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32(31):8010-8020.
128. Beduneau A., Hindre F., Clavreul A., Leroux J.C., Saulnier P., Benoit J.P. Brain targeting using novel lipid nanovectors. J Control Release 2008, 126(1):44-49.
129. Ren J., Shen S., Wang D., Xi Z., Guo L., Pang Z., et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with Angiopep-2. Biomaterials 2012, 33(11):3324-3333.
130. Huang S., Li J., Han L., Liu S., Ma H., Huang R., et al. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 2011, 32(28):6832-6838.
131. Sun X., Pang Z., Ye H., Qiu B., Guo L., Li J., et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an Angiopep-conjugated liposome. Biomaterials 2012, 33(3):916-924.
132. Gao H., Qian J., Cao S., Yang Z., Pang Z., Pan S., et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012, 33(20):5115-5123.
133. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7(12):779-786.
134. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8(2):137-143.
135. Hua M.Y., Liu H.L., Yang H.W., Chen P.Y., Tsai R.Y., Huang C.Y., et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials 2011, 32(2):516-527.
136. Chertok B., David A.E., Yang V.C. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release 2011, 155(3):393-399.
137. Wang H., Su W., Wang S., Wang X., Liao Z., Kang C., et al. Smart multifunctional core-shell nanospheres with drug and gene co-loaded for enhancing the therapeutic effect in a rat intracranial tumor model. Nanoscale 2012, 4(20):6501-6508.
138. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42(6):463-478.
139. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003, 20(3):409-416.
140. Parodi A., Quattrocchi N., van de Ven A.L., Chiappini C., Evangelopoulos M., Martinez J.O., et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013, 8(1):61-68.